Key Model for SHPT Drug Development

Secondary hyperparathyroidism (SHPT), abbreviated as secondary hyperparathyroidism, refers to a chronic compensatory clinical manifestation in which the parathyroid gland is stimulated by low blood calcium, low blood magnesium, or high blood phosphorus for a long time in chronic renal insufficiency, intestinal malabsorption syndrome, Fanconi syndrome, renal tubular acidosis, vitamin D deficiency or resistance, as well as pregnancy, lactation, and other conditions, resulting in excessive secretion of PTH to increase blood calcium, low blood magnesium, and reduce blood phosphorus. Long term parathyroid hyperplasia ultimately leads to the formation of functionally autonomous adenomas.